RT Journal Article
SR Electronic
T1 The testing of the DAC algorithm for classifying Lymphoma Cell of Origin samples using HTG’s targeted gene expression system
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.14.22270303
DO 10.1101/2022.04.14.22270303
A1 Davies, John R.
A1 Care, Matthew A.
A1 Mell, Tracey
A1 Barrans, Sharon
A1 Burton, Cathy
A1 Westhead, David R.
YR 2022
UL http://medrxiv.org/content/early/2022/04/18/2022.04.14.22270303.abstract
AB An implementation of the windows based DLBCL automatic classification (DAC) algorithm for determining cell of origin (COO) written in the R language and designed for use with the HTG EdgeSeq Reveal Software package is described. Classifications using the new implementation (DAC-R) were compared to the those using the original version (DAC-Win), the HTG DLBCL COO classifier, the HTG EdgeSeq Reveal DLBCL algorithm. Classifications made using HTG data were tested for concordance with those made using WG-DASL data for the same samples. To analyse small numbers of samples a background dataset was developed to allow for the reliable classification of individual cases. Classification accuracy was assessed using percentage of agreement of discrete classification groups and Pearson correlation of probability scores where appropriate. In the data tested it was seen that the correlation of probability scores for DAC-R and DAC-Win was 0.9985 or higher. Agreement with the HTG DLBCL COO classifier was 85.1% and agreement with the HTG EdgeSeq Reveal DLBCL algorithm was also high (Pearson correlation of GCB probabilities = 0.91). Agreement between classifications made using HTG and WG-DASL data was also high (83.7%). In summary, the R based algorithm of DAC successfully replicates the functionality of the original routine and produces comparable COO calls in data produced from the HTG Pan B-Cell Lymphoma Panel to the other methods listed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by Bloodwise grant number 15002: Precision Medicine for Aggressive Lymphoma. The Randomized Evaluation of Molecular-Guided Therapy for DLBCL With Bortezomib (REMoDL-B) trial was endorsed by Cancer Research UK, reference number CRUKE/10/024, and Janssen-Cillag provided funding. D.R.W. acknowledges UK Medical Research Council grant MR/L01629X/1 for infrastructure support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval for the MaPLe study was confirmed by the North West - Liverpool Central Research Ethics Committee (REC reference number 14/NW/1128). The REMoDLB and HMRN data are publicly available.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe REMoDLB data is presently available at GEO The HMRN data is presently available at GEO The MaPle data is part of an ongoing study and is not presently available at this time. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117556 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE181063